IOVA (Iovance Biotherapeutics) operates in the rapidly expanding autologous T-cell therapy segment of immuno-oncology, targeting solid tumors with tumor-infiltrating lymphocyte (TIL) technology. The global cell-therapy market is projected to exceed $40 billion by 2030, driven by rising cancer incidence and accelerating regulatory acceptance of living-drug platforms. Key public competitors advancing TIL or related adoptive cell therapies include Gileads Kite (GILD), Bristol Myers (BMY) via its Juno legacy assets, and Marker Therapeutics (MRKR); private rivals such as Instil Bio and Turnstone Biologics also vie for manufacturing scale and solid-tumor efficacy leadership.
| Score | Power Grid | T-Grid | Price |
|---|---|---|---|
Price action strength has been developing over the past 10 to 15 sessions. Longer term directional characteristics indicate bullishness. A well established uptrend is underway. The last 2 weeks are showing increasing amounts of bullish volume. Prices have been successively closing up, especially in recent sessions. The last session was bullish. Sortino Ratio indicates lowered risk. (5.04) AGL Ratio indicates positive medium term expectancy. (1.27) Overall Market Index (^GSPC) is trending Bearish - Strong.
Analysis bypassed - you do not have access to this research.
Analysis Date: 2026/09/16